Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Schizophrenia
Interventions
Atomoxetine
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Brentwood, New York • New York, New York
Conditions
Methamphetamine Abuse, Methamphetamine Dependence
Interventions
Atomoxetine, then Placebo, Placebo, then Atomoxetine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 1 Interventional Accepts healthy volunteers

A Gene by Medication Interaction to the Acute Effects of Alcohol

NCT01343628
Conditions
Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions
Placebo Comparator, Active Comparator: Atomoxetine, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 45 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Charlottesville/ Richmond, Virginia
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Monarch Medical Research
Other
Eligibility
6 Years to 18 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Norfolk, Virginia
Completed Phase 1Phase 2 Interventional Results available

Atomoxetine and Oxybutynin in Obstructive Sleep Apnea

NCT02908529
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Combination product of Atomoxetine and Oxybutynin, Placebo, 2 tablets
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Atomoxetine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
13 Years to 16 Years
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
21
States / cities
Pasadena, California • Rolling Hills Estates, California • Spring Valley, California + 18 more
Conditions
Traumatic Brain INjury
Interventions
atomoxetine, placebo
Drug
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Englewood, Colorado
Completed Not applicable Interventional Accepts healthy volunteers Results available

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

NCT00399763
Conditions
Attention Deficit Hyperactivity Disorder, Substance Abuse
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
12 Years to 19 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Attention Deficit Disorder With Hyperactivity, Marijuana Abuse
Interventions
Atomoxetine, placebo
Drug · Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
14 Years to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Results available

Cognitive Decline in Non-demented PD

NCT01340885
Conditions
Parkinson's Disease
Interventions
Strattera, Exelon, Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
ADHD
Interventions
Pediasure, Nutritional counseling
Dietary Supplement · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 9 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Mixed salts of a single-entity amphetamine, Atomoxetine hydrochloride
Drug
Lead sponsor
Shire
Industry
Eligibility
19 Years to 25 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
6 Years to 17 Years
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
20
States / cities
Dothan, Alabama • Anaheim, California • Imperial, California + 17 more
Conditions
Schizophrenia
Interventions
olanzapine, atomoxetine, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
20
States / cities
Cerritos, California • Chula Vista, California • Garden Grove, California + 15 more
Conditions
Obstructive Sleep Apnea (OSA)
Interventions
Positive airway pressure (PAP) therapy, Sleep dental device, Atomoxetine-oxybutynin
Device · Drug
Lead sponsor
Sairam Parthasarathy
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
4
States / cities
Tucson, Arizona • Redwood City, California • Miami, Florida + 1 more
Conditions
ADHD NOS
Interventions
atomoxetine (Strattera)
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Alzheimer Disease
Interventions
atomoxetine hydrochloride, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Sherman Oaks, California • Rochester, New York • Wichita Falls, Texas
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
LDX Treatment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Conditions
Cocaine Dependence
Interventions
d-Amphetamine; Atomoxetine
Drug
Lead sponsor
University of Kentucky
Other
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Sugar Pill
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
7 Years to 12 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Cincinnati, Ohio
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

NCT01678209
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Conditions
ADHD, Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate, Atomoxetine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 12 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Conditions
Attention Deficit Disorder With Hyperactivity, Substance-Related Disorders
Interventions
Atomoxetine hydrochloride, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
15 Years to 30 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts